Elsevier

The Lancet

Volume 350, Issue 9071, 12 July 1997, Pages 127-133
The Lancet

Seminar
Hypertrophic cardiomyopathy

https://doi.org/10.1016/S0140-6736(97)01282-8Get rights and content

Section snippets

Nomenclature, definition and prevalence

HCM has been known by a confusing multitude of names, largely reflecting its heterogeneity, with many individual investigators characterising the disease on the basis of the most obvious clinical feature apparent in a particular cohort of patients.1, 2 There has even been uncertainty as to whether HCM is best regarded as a single but diverse disease entity, or rather as a group of related and phenotypically similar disorders.

HCM has become the preferred name because, unlike many other terms

Genetic defects

HCM is a mendelian trait with an autosomal dominant pattern of inheritance. Over the past few years, laboratory and clinical studies have defined several gene mutations that cause HCM, and in the process have provided further evidence for the heterogeneity of the disorder.3, 5, 9 HCM can be caused by several mutations in any one of four genes that encode proteins of the cardiac sarcomere: β-myosin heavy-chain gene on chromosome 14; cardiac troponin T on chromosome 1; α-tropomyosin on chromosome

Left-ventricular hypertrophy

In HCM, the distribution of hypertrophy (at end-diastole) is almost always asymmetrical (figure 1), but there is substantial structural diversity, and no particular phenotypic expression of HCM can be regarded as “classic” or typical of the overall disease.6 Absolute left-ventricular wall thicknesses in clinically identified patients range broadly from mildly increased (13–15 mm; normal ≤12 mm) to massively increased, including the most substantial hypertrophy observed in any cardiac disease

Pathophysiology

The symptoms of HCM include most prominently those of pulmonary congestion (exertional dyspnoea, fatigue, orthopnoea, and paroxysmal nocturnal dyspnoea), and chest pain, which may be typical of angina. However, impaired consciousness (syncope, near-syncope, or lightheadedness) and palpitations are also commonly involved. Because the pathophysiology of HCM is complex and incompletely defined, the precise mechanisms by which each of these symptoms occur in all patients are not entirely resolved.

Natural history and treatment

HCM is a unique disease by virtue of its clinical expression in all phases of life from infancy to old age. The natural history is typically variable.1, 2, 7, 25, 28, 29, 30, 31, 32 Although clinical course is generally stable over long periods, it can be punctuated by adverse clinical events, including periodic or progressive symptoms of heart failure, sudden cardiac death, and peripheral embolisation.25, 28, 29, 30, 31

Full appreciation of the clinical implications of HCM requires an awareness

First page preview

First page preview
Click to open first page preview

References (45)

  • W McKenna et al.

    Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features

    Am J Cardiol

    (1981)
  • MJ Kofflard et al.

    Prognosis in hypertrophic cardiomyopathy: a retrospective study

    Am J Cardiol

    (1993)
  • BJ Maron et al.

    Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history

    Am J Cardiol

    (1993)
  • BJ Maron et al.

    Hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases, and mitral valve prolaspe. Task Force 3. In: 26th Bethesda Conference. Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities (Maron BJ, Mitchell JH)

    J Am Coll Cardiol

    (1994)
  • WP Fay et al.

    Natural history of hypertrophic cardiomyopathy in the elderly

    J Am Coll Cardiol

    (1990)
  • X Jeanrenaud et al.

    Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy

    Lancet

    (1992)
  • RA Nishimura et al.

    Dual-chamber pacing for patients with hypertrophic obstructive cardiomyopathy: a prospective randomized, double-blind cross-over study

    J Am Coll Cardiol

    (1997)
  • BJ Maron et al.

    Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy

    N Engl J Med

    (1987)
  • H Watkins et al.

    Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy

    N Engl J Med

    (1992)
  • K Schwartz et al.

    Molecular basis of familial cardiomyopathies

    Circulation

    (1995)
  • AJ Marian et al.

    Recent advances in the molecular genetics of hypertrophic cardiomyopathy

    Circulation

    (1995)
  • P Spirito et al.

    Management of hypertrophic cardiomyopathy

    N Engl J Med

    (1997)
  • Cited by (0)

    View full text